GGS
UTHR icon

Galvin Gaustad & Stein’s United Therapeutics UTHR Stock Holding History

Galvin Gaustad & Stein’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-37,086
Closed -$10.7M – 210
2025
Q2 		$10.7M Buy
37,086
+6,598
+22% +$1.97M 0.92% 47
2025
Q1 		$9.4M Buy
30,488
+3,976
+15% +$1.36M 0.84% 51
2024
Q4 		$9.35M Buy
26,512
+1,505
+6% +$553K 0.84% 48
2024
Q3 		$8.96M Buy
+25,007
New +$8.45M 0.8% 52

Other funds holding UTHR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Galvin Gaustad & Stein's UTHR Position: Q3 2025 in Review

Galvin Gaustad & Stein sold out of United Therapeutics (UTHR) in Q3 2025, closing a stake of 37,086 shares — an estimated $10.7M sold.

Galvin Gaustad & Stein first reported a position in UTHR in Q3 2024 and held it in 4 quarters. The position peaked at $10.7M in Q2 2025. 707 funds tracked by Wall St. Rank hold UTHR as of Q3 2025.

  • Galvin Gaustad & Stein reported no remaining United Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Galvin Gaustad & Stein sold 37,086 United Therapeutics shares in Q3 2025, an estimated $10.7M.
  • Galvin Gaustad & Stein first reported a position in United Therapeutics in Q3 2024 and held it in 4 quarters.
  • Galvin Gaustad & Stein's United Therapeutics position peaked at $10.7M in Q2 2025.
  • 707 funds tracked by Wall St. Rank held United Therapeutics as of Q3 2025.

Based on Galvin Gaustad & Stein's 13F filing for Q3 2025, filed 22 Oct 2025.